# Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

> **NCT05808634** · PHASE1 · RECRUITING · sponsor: **BioAtla, Inc.** · enrollment: 168 (estimated)

## Conditions studied

- Advanced Adenocarcinoma

## Interventions

- **DRUG:** BA3182

## Key facts

- **NCT ID:** NCT05808634
- **Lead sponsor:** BioAtla, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-14
- **Primary completion:** 2028-09-15
- **Final completion:** 2028-09-15
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05808634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05808634, "Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05808634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*